Laboratorios Richmond S.A.C.I.F. Stocks

ARS 1710Last Updated 17.03.2026

Issuer Rating

3/7

Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

ARS 103.20M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
ARS 1710
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East. Laboratorios Richmond S.A.C.I.F. was founded in 1935 and is headquartered in Buenos Aires, Argentina.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is of fair value on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks